What do we know so far about the Omicron BA.2 variant?
Omicron BA.2 variant is on the rise globally. Image: Unsplash/Adam Nieścioruk
- BA.2 is a new sub-variant of the Omicron version of the coronavirus.
- Scientists say it's more transmissable, harder to track and now dominant worldwide causing a significant rise in COVID-19 cases in some countries.
- They add that, similarly to Omicron, vaccines are less effective against this new strain but booster jabs can offer significant protection and it is no more likely to cause serious disease.
A sub-variant of the highly transmissible Omicron version of coronavirus known as BA.2 is now dominant worldwide, prompting surges in many countries in Europe and Asia and raising concern over the potential for a new wave in the United States.
Below is a summary of what is known about Omicron BA.2 variant.
How has the Forum navigated the global response to COVID-19?
Omicron BA.2 variant is more transmissible
Omicron BA.2 variant now represents nearly 86% of all sequenced cases, according to the World Health Organization. It is even more transmissible than its highly contagious Omicron siblings, BA.1 and BA.1.1, however the evidence so far suggests that it is no more likely to cause severe disease.
As with the other variants in the Omicron family, vaccines are less effective against BA.2 variant than against previous variants like Alpha or the original strain of coronavirus, and protection declines over time. However, according to UK Health Security Agency data, protection is restored by a booster jab, particularly for preventing hospitalisation and death. https://www.reuters.com/business/healthcare-pharmaceuticals/covid-booster-provides-protection-over-65s-after-15-weeks-uk-data-2022-03-24/
Global picture
The rise of Omicron BA.2 variant has been blamed for recent surges in China as well as record infections in European countries like Germany and the UK. Yet some European countries are now seeing a slower uptick in new cases, or even a decline.
BA.2 has been called the "stealth variant" because it is slightly harder to track. A missing gene in BA.1 allowed it to be tracked by default through a common PCR test. BA.2 variant and another sibling, BA.3, which is also increasing in prevalence but is currently at low levels, can only be found by genomic sequencing, which some countries do more of than others.
Can BA.2 variant reinfect people?
A key concern about Omicron BA.2 variant was whether it could re-infect people who had already had BA.1, particularly as a number of countries seemed to be experiencing "double peaks" in infection rates surprisingly close together. But data from both the UK and Denmark have shown that while Omicron can reinfect people who had other variants, such as Delta, only a handful of BA.2 reinfections in people who had BA.1 have been found so far among tens of thousands of cases.
Scientists say a possible explanation for the recent rise in BA.2 variant could be that the global uptick happened at the same time that many countries lifted public health interventions.
"In some ways, it could just be that Omicron BA.2 was the variant that was circulating when all these people stopped wearing masks," said Dr Andrew Pekosz, a virologist at the Johns Hopkins Bloomberg School of Public Health in Baltimore.
As such, other U.S. experts such as Eric Topol, director of the Scripps Research Translational Institute in La Jolla, California, said it was "a little too early" to call whether the U.S. too would see a significant BA.2 wave.
But whatever the reason for Omicron BA.2 variant rise, scientists said it was a reminder that the virus continues to cause harm, particularly among unvaccinated, under-vaccinated and vulnerable populations.
"It is still a huge public health problem and it is going to continue to be," said Mark Woolhouse, an epidemiologist at the University of Edinburgh.
Don't miss any update on this topic
Create a free account and access your personalized content collection with our latest publications and analyses.
License and Republishing
World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.
The views expressed in this article are those of the author alone and not the World Economic Forum.
Stay up to date:
COVID-19
Forum Stories newsletter
Bringing you weekly curated insights and analysis on the global issues that matter.
More on Health and Healthcare SystemsSee all
Fernando J. Gómez and Elia Tziambazis
December 20, 2024